[1] Wu X Y,Yang M,Xie Y S,et al. Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort[J].Clin Rheumatol, 2018.
[2] Tselios K,Gladman D D,Su J,et al. Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study[J].J Rheumatol, 2017, 44(12): 1841-2849.
[3] Ahn G Y,Kim D,Won S,et al. Prevalence, risk factors, and impact on mortality ofneuropsychiatric lupus: a prospective, single-center study[J]. Lupus, 2018, 27(8): 1338-1347.
[4] Tay Sh,Fairhurst Am,Mak A. Clinical utility of circulating anti-N-methyl-D-aspartate receptor subunits NR2A/B antibody for the diagnosis of neuropsychiatric syndromes in systemic lupus erythematosus and Sjögren’s syndrome:[J].Autoimmun Rev, 2017, 16(2): 114-122.
[5] Hughes E,Peng X,Gleichman Aj. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis[J]. J Neurosci, 2010, 30(17): 5866-5975.
[6] Bravo-zehnder M,Toledo E M,Segovia M F,et al. Anti-Ribosomal P Protein Autoantibodies From Patients With Neuropsychiatric Lupus Impair Memory in Mice[J]. Arthritis Rheumatol, 2015, 67(1): 204-214.
[7] Cohen D,Rijnink E C,Nabuurs R J, et al.Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement[J]. Rheumatology, 2017, 56(1): 77-86.
[8] Magro-checa C,Schaarenburg R A,Beaart H J,et al.Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus[J]. Lupus, 2016, 25(8): 878-888.
[9] Tan Z,Zhou Y B,Li X P,et al.Brain magnetic resonance imaging, cerebrospinal fluid, and autoantibody profile in 118 patients with neuropsychiatric lupus[J]. Clin Rheumatol, 2018, 37(1): 227-233.
[10] Gupta N,Ganpati A,Mandal S,et al.Mycophenolate mofetil and deflazacort combinationin neuropsychiatric lupus: a decade of experience from a tertiarycare teaching hospital in southern India[J]. Clin Rheumatol, 2017, 36(10): 2273-2279.
[11] Toledano P,Orueta R,Rodríguez-pintp I,et al.Peripheral nervous system involvement in systemic lupus erythematosus: prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre[J].Autoimmun Rev, 2017, 16(7): 750-755.
[12] Alessi H,Dutra L A,Braga P,et al. Neuropsychiatric lupus in clinical practice[J]. Arq Neuropsiquiatr, 2016, 74(12): 1021-1030.
[13] Kozora E,Eilison M C,West S. Reliability and Validity of the Proposed AmericanCollege of Rheumatology NeuropsychologicalBattery for Systemic Lupus Erythematosus[J]. Arthritis Rheum, 2004, 51(5): 810-818.
[14] Rayes H A,Tani C,Kwan A,et al. What is the prevalence of cognitive impairment in lupus andwhich instruments are used to measure it? A systematic review andmeta-analysis[J].Semin Arthritis Rheum, 2018, 48(2):240-255.
[15] Paez-venegas N,Jordan-estrada B,Chavarria-avila E,et al. The montreal cognitive assessment test: a useful tool in screening of cognitive impairment in patients with systemic lupus erythematosus[J]. J Clin Rheumatol, 2018.
[16] Nantes S G,Su J,Dhaliwal A,et al.Performance of Screening Tests for Cognitive Impairment in Systemic Lupus Erythematosus[J]. J Rheumatol, 2017, 44(11): 1583-1589.
[17] Macêdo E,Appenzeller S,Costallat L T. Assessment of the hospital anxiety and depression scale (HADS) performance for the diagnosis of anxiety in patients with systemic lupus erythematosus[J]. Rheumatol Int, 2017, 37(12): 1999-2004.
[18] Cannerfelt B,Nystedt J,Jönsen A,et al. White matter lesions and brain atrophy in systemic lupus erythematosus patients: correlation to cognitive dysfunction in a cohort of systemic lupus erythematosus patients using different definition models for neuropsychiatric systemic lupus erythematosus[J]. Lupus, 2018, 27(7): 1140-1149.
[19] Sarbu N,Toledano P,Calvo A,et al. Advanced MRI techniques: biomarkers in neuropsychiatric lupus[J]. Lupus , 2017, 26(5): 510-516.
[20] Shaharir S S,Osman S S,Rani SA-Md,et al.Factors associated with increased white matter hyperintense lesion(WMHI) load in patients with systemic lupus erythematosus (SLE)[J]. Lupus, 2018, 27(1): 25-32.
[21] Kalinowska-lyszczarz A,Pawlak M A,Pietrzak A,et al. Distinct regional brain atrophy pattern in multiple sclerosis and neuropsychiatric systemic lupus erythematosus patients[J]. Lupus, 2018, 27(10): 1624-1635.
[22] Al-obaidi M,Saunders D,Brown S,et al. Evaluation of magnetic resonance imaging abnormalitiesin juvenile onset neuropsychiatric systemic lupus erythematosus[J]. Clin Rheumatol, 2016, 35(10): 2449-2456.
[23] Sarbu N,Sarbu M I,Bargall N,et al. Future Perspectives in the Diagnosis of Neuropsychiatric Lupus by Advanced Magnetic Resonance Imaging Techniques [J].Curr Rheumatol Rev, 2018, 14(3): 213-218.
[24] Costallat B L,Ferreira D M,Tamireslapa A,et al.Brain diffusion tensor MRI in systematic lupus erythematosus: Asystematic review[J].Autoimmun Rev, 2018, 17(1): 36-43.
[25] Magro-checa C,Ercan E,Wolterbeek R,et al.Changes in white matter microstructure suggest inflammatory origin of neuropsychiatric systemic lupus erythematosus [J].Arthritis Rheum, 2016, 68(8): 1945-1954.
[26] Wang P I,Cagnoli P C,Mccune W J,et al. Perfusion-weighted MR Imaging in Cerebral Lupus Erythematosus[J]. Acad Radiol, 2012, 19(8): 965-970.
[27] Papadaki E,Fanouriakis A,Kavroulakis E,et al. Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus[J]. Ann Rheum Dis, 2018, 77(3): 441-448.
[28] Postal M,Lapa A T,Reis F,et al. Magnetic resonance imaging in neuropsychiatric systemic lupuserythematosus: current state of the art and novel approaches[J]. Lupus, 2017, 26(5): 517-521.
[29] Niu C,Tan X L,Liu X J,et al.Cortical thickness reductions associate with abnormalresting-state functional connectivity in non-neuropsychiatricsystemic lupus erythematosus[J].Brain Imaging Behav, 2018, 12(3): 674-684.
[30] Saito T,Tamura M,Chiba Y,et al.Regional cerebral glucose metabolism in systemic lupus erythematosus patients with major depressive disorder[J].J Neurol Sci, 2017, 379: 127-130.
[31] Fang H L,Lan L K,Qu Y Z,et al.Differences between centralnervous system infection andneuropsychiatricsystemiclupuserythematosus inpatients with systemiclupuserythematosus[J]. J Int Med Res, 2018, 46(1): 485-491.
[32] Bortoluzzi A,Scirè C A,Bombardieri S,et al. Development and validation of a new algorithm forattribution of neuropsychiatric events in systemic lupus erythematosus[J]. Rheumatology, 2015, 54(5): 891-898.
[33] Waterhouse E, Wallace D J, Winer J B. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes[J].Arthritis Rheum, 1999, 42(4): 599-608.
[34] Zardi E M,Giorgi C,Zardi D M. Diagnostic approach to neuropsychiatric lupuserythematosus: what should we do?[J]. Postgrad Med, 2018, 130(6) : 536-547.
[35] Monahan R C,Beaart-van-de V L,Steup-beekman G M,et al.Neuropsychiatric symptoms in systemic lupus erythematosus:impact on quality of life[J]. Lupus, 2017, 26(12): 1252-1259.
[36] Tanaka Y. Neuropsychiatric Systemic Lupus Erythematosus[J]. Brain Nerve, 2016, 68(9): 1035-1048.
[37] Barile-fabris L,Ariza-andraca R,Olguι’n-ortegaL,et al. Controlled clinical trial of IV cyclophosphamide versus IVmethylprednisolone in severe neurological manifestations insystemic lupus erythematosus[J]. Ann Rheum Dis, 2005, 64(4): 620-625.
[38] Fanouriakis A,Pamfil C,Sidiropoulos P,et al. Cyclophosphamide in combination with glucocorticoidsfor severe neuropsychiatric systemic lupus erythematosus:a retrospective, observational two-centre study[J]. Lupus, 2016, 25(6): 627-636.
[39] Lei H W,Wang J Y,Dang Q J,et al. Neuropsychiatric involvement in lupus is associated with theNogo-a/NgR1 pathway[J]. J Neuroimmunol,2017, 311: 22-28.
[40] Hanly J,Kozora E,Beyea S D,et al. Nervous system disease in Systemic Lupus Erythematosus: Current status and future directions[J]. Arthritis Rheum, 2019,71(1):33-42.
[41] Faria R,Gonçalves J,Dias R. Neuropsychiatric Systemic Lupus Erythematosus Involvement: Towards a Tailored Approach to Our Patients? [J]. Rambam Maimonides Med J, 2017, 8(1):276.